12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Optimer, AstraZeneca sales and marketing update

Optimer granted AstraZeneca exclusive rights to commercialize Dificid fidaxomicin in South and Central America, Mexico and the Caribbean. Optimer will receive $1 million up front and is eligible for up to $3 million in milestones for the first commercial sale in certain...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >